Sartorius Stedim Biotech Introduces Advanced System for Agar and Membrane Transfer
Sartorius Stedim Biotech (SSB), a leading global supplier for the pharmaceutical and biotech industries, is introducing Microsart @media to complement Microsart @vance, a product line for microbiological quality control in these sectors.
Microsart @media are agar media dishes for microbial limits testing according to the USP (Chapter <61>) and EP (Chapter 2.6.12). They are pre-filled with various agar media types, such as Tryptic Soy Agar or R2A Agar, sterile packaged and ready-to-use in combination with Microsart @filter units. Moreover, the Microsart @media features an innovative patented lid that allows touch-free transfer of the filter membrane onto the media without using any tweezers. In addition, easy access to the colonies after incubation is given due to the liftable lid. The intelligent design and ease of use eliminates almost all handling mistakes.
The combination of Microsart @media and Microsart @filters introduce a brand-new agar and membrane transfer concept. Thanks to their concerted development the matching Microsart @media active lid fits perfectly onto the Microsart @filter base. The few steps required between sampling and incubation save time and labor, while delivering more reliable results. The touch-free membrane transfer eliminates membrane manipulation and handling, thereby minimizing a major source of secondary contamination.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.